Drug Trial Radar · NCT02565576
Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia Gravis
Last checked: Nov 19, 2026Latest source record: Jan 5, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
44
Actual
Start
Sep 29, 2015
Primary completion
Jul 31, 2017
Study completion Dec 19, 2017
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Oct 1, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate safety, tolerability, pharmacokinetics/pharmacodynamics and efficacy of CFZ533 as an add-on therapy to standard of care in patients with moderate to severe myasthenia gravis (MG).
Conditions
- Myasthenia Gravis, Generalized
Interventions
PlaceboDrug
CFZ533Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change From Baseline in the Quantitative Myastenia Gravis (QMG) Score at Week 25. Posterior Median Was Used as Measure Type.Time frame: week 25
Locations
15 sites in 5 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Québec, Quebec, Canada
Novartis Investigative Site
Aarhus, Denmark
Novartis Investigative Site
Copenhagen, Denmark
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Halle/S, Germany
Novartis Investigative Site
München, Germany
Novartis Investigative Site
Barnaul, Russia
Novartis Investigative Site
Kazan', Russia
Novartis Investigative Site
Novosibirsk, Russia
Novartis Investigative Site
S-Petersburg, Russia
Novartis Investigative Site
Samara, Samara Oblast, Russia
Novartis Investigative Site
Taipei, Taiwan
Novartis Investigative Site
Taipei, Taiwan
Novartis Investigative Site
Tainan, Taiwan ROC, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.